CMPS Snapshot
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin formulation, which is in Phase IIb clinical trial to treat patients with treatment-resistant depression. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is based in Cheshire, the United Kingdom.
Market Capitalization$2,020
Price to Sales0.00
Earnings per Share$0.0000
PE RatioNone
Most Recent Close$34.3400
52 Week High$None
52 Week Low$61.69
50-Day Moving Average$22.51
200-Day Moving Average$38.9215
All data are from Alpha Vantage as of today. For more infomation on CMPS see Stock Dividend, Valuation, Price and Financial Data for Investors